Now Reading: Government restricts cold medicine use for children under four
-
01
Government restricts cold medicine use for children under four
The government has restricted the manufacture, sale and distribution of all fixed dose combinations (FDCs) containing Chlorpheniramine Maleate and Phenylephrine Hydrochloride, mandating a warning that these medicines shall not be used in…
The government has restricted the manufacture, sale and distribution of all fixed dose combinations (FDCs) containing Chlorpheniramine Maleate and Phenylephrine Hydrochloride, mandating a warning that these medicines shall not be used in children below four years of age.
The decision, effective from publication in the official gazette, follows recommendations by an expert committee and the Drugs Technical Advisory Board (DTAB). The government noted that such combinations may pose risks to young children and that safer alternatives are available.
Manufacturers must display the warning on labels, package inserts and promotional literature. The notification was issued under Section 26A of the Drugs and Cosmetics Act, 1940. This follows an April 15, 2025 notification that restricted certain FDCs containing the same ingredients.
Indian Opinion Analysis
Both The Hindu and Livemint report the same regulatory action with near-identical factual content, leading with the restriction and the age limit. Neither source includes any criticism of the government or the industry, and neither adds opposition or expert dissent. The coverage is uniform straight reporting, reflecting a consensus that the move is a straightforward public health measure. The careful reader should note that this is the second such notification in 16 months, indicating a phased tightening of regulations on paediatric FDCs. Watch for whether manufacturers challenge the notification or comply by the effective date.
Coverage: 2 sources, 2 neutral
Sources (2): thehindu.com (neutral report), livemint.com (neutral report)
This story was synthesised by AI from the 2 sources linked above.
